Navigation Links
Spirit II explores long-term performance of XIENCE V stent
Date:3/31/2008

CHICAGO, Ill. (March 31, 2008) Early results of the SPIRIT II study showed that the XIENCE V stent was superior to the Taxus stent in six-month findings on angiography and trended better on one-year clinical outcomes. Now, a new analysis shows that after two years, the investigational everolimus-coated XIENCE V stent may continue to hold a clinical edge over its paclitaxel-coated competitor.

The two-year findings of the SPIRIT II study are being reported today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC).

Patrick W. Serruys, MD, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands, led the SPIRIT II study. He and his colleagues recruited 300 patients from 28 medical centers in Europe, New Zealand and India who needed stenting of up to two new coronary lesions. Patients were randomly assigned to treatment with the XIENCE V everolimus-eluting stent or the Taxus paclitaxel-eluting stent.

The study primarily set out to document any differences in the amount of arterial tissue that grew into the stents at six months (in-stent late loss). As previously reported, the results were significantly better for the XIENCE V stent when compared to the Taxus stent. At one-year follow-up, the combined rates of major adverse cardiac events (MACE), consisting of cardiac death, heart attack and repeat procedure to treat the target lesion, trended better in the XIENCE V group.

New data from a late-stage evaluation report demonstrates that the XIENCE V stent continues to show a trend toward improved clinical outcomes compared to the Taxus stent at two years, however, the trial was not statistically powered to show differences in clinical endpoints. The overall MACE rate at two years was 40 percent lower in patients treated with the XIENCE V stent (6.6 percent vs. 11.0 percent in the Taxus group). Repeat procedures to treat the target lesion were performed in 3.8 percent and 6.8 percent of patients, respectively, a 44 percent reduction favoring the XIENCE V stent. Similarly, the rates of heart attack were 2.8 percent and 5.5 percent, respectively, a 49 percent reduction, and the rates of cardiac death were 0.5 percent and 1.4 percent, respectively, a 64 percent reduction. There was no difference in the rates of blood clotting inside the stent, or stent thrombosis, at two years.

In the 117 patients who had follow-up angiography at two years, there was no significant difference in the rates of re-narrowing of at least 50 percent (binary restenosis) within the stents (2.1 percent with the XIENCE V stent vs. 2.9 percent with the Taxus stent). In-stent late loss was virtually identical (0.33 mm vs. 0.34 mm, on average, respectively).

Dr. Serruys will present the two-year results of the SPIRIT II study on Monday, March 31 at 8:45 a.m. CDT in the Grand Ballroom, S100.


'/>"/>

Contact: Kathy Boyd David
pr@scai.org
717-422-1181
Weber Shandwick Worldwide
Source:Eurekalert

Related medicine news :

1. Spiritual Health Experts Speak at Chaplains Conference in Pittsburgh March 8-12
2. Most Psychiatrists Open to Discussing Spiritual Concerns
3. Health Care Bill Omits Access to Spiritual Care
4. New Yorkers Deserve Access to Spiritually Based Healing
5. Spirituality Helps Older Black Women Beat Hypertension
6. Living Your Best Life: Adjusting Mind, Body and Spirit
7. Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai
8. Wine, women and... spirits, beer and breast cancer risk
9. USA TODAY Concludes Spirit of the USA Charity Program as Part of Newspapers 25th Anniversary Celebration
10. Spiritual Healer/Psychic-Medium Reaches International Status!
11. USA TODAY Continues Spirit of the USA Charity Program as Part of Newspapers 25th Anniversary Celebration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: